Why ESG Is Now a Revenue and Risk Issue in Clinical Research - Voices of SCOPE скачать в хорошем качестве

Why ESG Is Now a Revenue and Risk Issue in Clinical Research - Voices of SCOPE

In this Voices of SCOPE conversation, I sat down with Dr. Otis Johnson, Founder of Vantix Operations, to unpack the real business case for ESG and sustainability in clinical trials. This is not about messaging or intent. It is about risk, revenue, and whether sponsors and suppliers even make it onto the RFP list. Otis explains how ESG scorecards are already being used behind the scenes, how companies can be quietly excluded before bidding even begins, and why suppliers are often more exposed than sponsors. He also shares practical steps organizations can take now, from EcoVadis to carbon disclosure, to avoid being screened out. If you work in clinical operations, vendor management, procurement, or leadership, this is a very real conversation about staying competitive. #VoicesOfSCOPE #SCOPEsummit #ClinicalResearch #ClinicalOperations #ESG #Sustainability #VendorManagement #Pharma #Biopharma #CROs __________________________________________________________________________ Join the SCOPE 365 Community & Stay Informed about the Entire Clinical Trials Industry! 📰 Clinical Research News Online: https://bit.ly/4ndSLTa 🎟️ SCOPE Summit: https://bit.ly/3JJtJNf 🎫 SCOPE Summit Europe: https://bit.ly/45OHhjh 🤝 ClinEco - Clinical Trials Ecosystem & Marketplace: https://bit.ly/47KxsnR 🔗 SCOPE 365 LinkedIn Community: https://bit.ly/3VyhoOw